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Abstract
Racial differences exist in the severity of systemic sclerosis (SSc). To enhance our knowledge about SSc in African Americans, we
established a comprehensive clinical database from the largest multicenter cohort of African American SSc patients assembled to
date (the Genome Research in African American Scleroderma Patients (GRASP) cohort).Editor: Francesco Carubbi.
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Morgan et al. Medicine (2017) 96:51 MedicineAfrican American SSc patients were enrolled retrospectively and prospectively over a 30-year period (1987–2016), from 18
academic centers throughout the United States. The cross-sectional prevalence of sociodemographic, clinical, and serological
features was evaluated. Factors associated with clinically significant manifestations of SSc were assessed using multivariate logistic
regression analyses.
The study population included a total of 1009 African American SSc patients, comprised of 84% women. In total, 945 (94%)
patients met the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification
criteria for SSc, with the remaining 64 (6%) meeting the 1980 ACR or CREST (calcinosis, Raynaud’s phenomenon, esophageal
dysmotility, sclerodactyly, telangiectasia) criteria. While 43% were actively employed, 33% required disability support. The majority
(57%) had the more severe diffuse subtype and a young age at symptom onset (39.1±13.7 years), in marked contrast to that
reported in cohorts of predominantly European ancestry. Also, 1 in 10 patients had a severe Medsger cardiac score of 4. Pulmonary
fibrosis evident on computed tomography (CT) chest was present in 43% of patients and was significantly associated with anti-
topoisomerase I positivity. 38% of patients with CT evidence of pulmonary fibrosis had a severe restrictive ventilator defect, forced
vital capacity (FVC) 50% predicted. A significant association was noted between longer disease duration and higher odds of
pulmonary hypertension, telangiectasia, and calcinosis. The prevalence of potentially fatal scleroderma renal crisis was 7%, 3.5 times
higher than the 2% prevalence reported in the European League Against Rheumatism Scleroderma Trials and Research (EUSTAR)
cohort.
Our study emphasizes the unique and severe disease burden of SSc in African Americans compared to those of European
ancestry.
Abbreviations: ACE = angiotensin converting enzyme, ACR/EULAR = American College of Rheumatology/European League
Against Rheumatism, ANA= antinuclear antibody, ANOVA= analysis of variance, CI= confidence interval, CREST= calcinosis, CT=
computed tomography, dcSSc = diffuse cutaneous systemic sclerosis, DLCO = diffusing capacity of the lung for carbon monoxide,
esophageal dysmotility, EUSTAR = European League Against Rheumatism Scleroderma Trials and Research, EUSTAR = European
League Against Rheumatism Scleroderma Trials and Research, FVC = forced vital capacity, GRASP = Genome Research in African
American Scleroderma Patients cohort, ILD = interstitial lung disease, lcSSc = limited cutaneous systemic sclerosis, mRSS =
modified Rodnan Skin Score, Musculoskeletal and Skin Diseases, NIAMS = National Institute of Arthritis, NIH = National Institutes of
Health, OR = odds ratio, PFTs = pulmonary function tests, Raynaud’s phenomenon, RP = Raynaud’s phenomenon, sclerodactyly,
SLE = systemic lupus erythematosus, SRC = scleroderma renal crisis, SSc = systemic sclerosis, telangiectasia, US = United States.
Keywords: African Americans, autoantibodies, systemic sclerosis
1. Introduction database and significant size of the GRASP cohort providesThere is evidence that racial differences exist in the susceptibility
to and severity of systemic sclerosis (scleroderma; SSc). African
Americans have a higher age-specific incidence and prevalence of
SSc compared to European Americans.[1,2] Moreover, the most
current national report of SSc-associated mortality in the United
States (US) noted death rates that peaked a decade earlier in
the African American population, with age-adjusted mortality
significantly higher in African Americans compared to European
Americans.[3]
The leading cause of mortality in SSc is attributed to
pulmonary complications, which occur in 70% to 90% of
patients.[4] The 10-year survival for SSc patients with interstitial
lung disease (ILD) is only 60%.[5] African ancestry is an
independent predictor of lung involvement in SSc.[6] Further-
more, the incidence of SSc-associated severe ILD[7] and
pulmonary hypertension[8,9] is reported to be higher in African
Americans than other ethnic groups.
Socioeconomic factors and impaired access to health care have
not fully accounted for thepredilectionofAfricanAmericans topoor
health outcomes.[10] Attempts to elucidate the factors influencing
increased disease severity have been hindered by the relatively small
size of available African American SSc cohorts.[11,12]
Accordingly, a multicenter SSc cohort database, the Genome
Research in African American Scleroderma Patients (GRASP)
clinical database, was established to enhance our understanding
of the phenotype of SSc in African Americans and identify factors
contributing to the severity of their disease. The GRASP cohort
consists of more than 1000 extensively phenotyped African
American SSc patients enrolled from academic centers through-
out the US. It is currently the largest multicenter cohort of African
American SSc patients. Consequently, the comprehensive clinical2adequate statistical power to perform informative multivariate
analyses.
In this paper, we describe the clinical and serological
characteristics of the GRASP cohort and report the results of
multivariate analyses, to identify factors associated with clinically
significant and severe manifestations of SSc in African Americans.
Additionally, we compare the findings in the GRASP cohort to
that reported in a multicenter cohort of predominantly European
ancestry.2. Methods
2.1. Study population
The GRASP clinical database was established in May 2013 and
includes socio-demographic and clinical characteristics of a US
cohort of exclusively African American SSc patients, enrolled
retrospectively and prospectively over a 30-year period (1987–
2016). African American race was ascertained by patient self-
identification. All patients met the 1980 American College of
Rheumatology (ACR) or 2013ACR/EULAR (European League
Against Rheumatism) classification criteria for systemic sclerosis;
or had at least 3 of 5 features of the CREST (calcinosis,
Raynaud’s phenomenon, esophageal dysmotility, sclerodactyly,
telangiectasia) syndrome.[13,14]2.2. Study protocol
Patients were enrolled from a total of 18 academic centers
throughout the US. The study was conducted in accordance with
the Declaration of Helsinki[15] and participating centers secured
local ethics committee approval prior to participant enrollment.
Morgan et al. Medicine (2017) 96:51 www.md-journal.comGRASP investigators documented clinical, serological and socio-
demographic data, including age, sex, dates of SSc diagnosis and
symptom onset, smoking status, immunosuppressive medication
use, history of malignancy and autoantibody status. The presence
of an overlapping autoimmune disease (rheumatoid arthritis,
systemic lupus erythematosus, inflammatory myopathy, Sjög-
ren’s syndrome) was ascertained based on established classifica-
tion criteria.[16–20]
Data from diagnostic studies including pulmonary function
tests (PFTs), echocardiograms, chest radiographs, and high-
resolution computed tomography (CT) scans of the chest and
right heart cardiac catheterizations were obtained. All data were
subsequently assembled in a clinical database, maintained at the
Johns Hopkins University coordinating site.
Disease onset was defined as the occurrence of the first ever
symptom attributed to SSc (Raynaud’s or non-Raynaud’s).
Disease duration was defined as the time from disease onset to the
date of sample collection for genetic analysis. SSc subtype was
classified as diffuse (dcSSc) or limited (lcSSc) based on the extent
of cutaneous involvement, as described by LeRoy et al.[21]
Patients were classified as having diffuse SSc if there was clinical
evidence of cutaneous fibrosis extending proximal to the elbows
or knees, at any time during the disease course.
The pattern of skin involvement was further classified into 4
subsets (Type 0,1,2,3) as previously defined by Cottrell et al.[22]
The degree of cutaneous fibrosis was quantitatively assessed
using the physician assigned modified Rodnan Skin Score
(mRSS).[23] The maximum mRSS and worst ever organ specific
severity scores were recorded for each patient. Organ-specific
severity scores were assigned in accordance with the revised
Medsger Severity Score for SSc.[24]
Target organ involvement was deemed to be present if the
respective Medsger Severity Score was≥1. Severe organ
involvement was defined as a Medsger Severity Score of 3
(severe) or 4 (end stage).[24] Accordingly, severe peripheral
vascular involvement was defined as the presence of digital tip
ulcerations or digital gangrene. An mRSS ≥30 was indicative of
severe cutaneous involvement. Severe gastrointestinal disease
included malabsorption syndrome, episodes of pseudo-obstruc-
tion or the requirement of total parenteral nutrition. For renal
disease, severe involvement was defined by a serum creatinine
level ≥3.0mg/dL, or the requirement for dialysis or renal
transplant. Skeletal muscle involvement was deemed to be severe
if proximal muscle weakness with less than grade 3/5 power was
evident on physical examination, or the patient required
ambulation aids. Severe cardiac disease was defined as a left
ventricular ejection fraction<40%, clinical signs of heart failure,
an arrhythmia requiring treatment, or heart transplant. Severe
pulmonary involvement was characterized by the presence of at
least one of the following: forced vital capacity (FVC) < 50% of
predicted, diffusing capacity of the lung for carbon monoxide
(DLCO) < 50% of predicted, moderate to severe pulmonary
hypertension, requirement for oxygen due to SSc-associated
pulmonary disease or lung transplant.2.3. Statistical analysis
The cross-sectional prevalence of clinical and serological features
in the GRASP cohort was determined using the data obtained at
the time of study enrollment. Clinical and socio-demographic
characteristics were compared between groups based on sex,
serological profile, and SSc subtype respectively, using t-test, chi-
square test, Fisher’s exact test, and one-way analysis of variance3(ANOVA) as appropriate. Factors associated with clinical
manifestations of SSc and severe organ involvement were
identified using multivariable logistic regression analyses includ-
ing covariates: sex (male versus female), SSc subtype (dcSSc
versus lcSSc), SSc-associated autoantibody status (anti-centro-
mere, anti-topoisomerase I or anti-RNA polymerase III positivi-
ty), age at first symptom onset and disease duration in years.
These variables were fixed in all analyses because of their clinical
relevance.
The date of onset of the first symptom attributed to SSc
(Raynaud’s or non-Raynaud’s) was used to calculate disease
duration. Sensitivity analyses were performed to ensure the
choice of disease onset (Raynaud’s onset versus first non-
Raynaud’s symptom onset) did not impact the magnitude or
significance of observed associations with relevant clinical
outcomes. The covariate of smoking status (ever versus never
smoked cigarettes) was included in multivariable logistic
regression analysis to determine factors associated with vascular
and cardiopulmonary involvement. Assumptions in the statistical
analyses were verified using normal probability and leverage
plots. Statistical significance was defined as a 2-sided P value 
.05. The dataset was analyzed using Stata Statistical Software
version 14.2 (College Station, TX).3. Results
3.1. Patient characteristics and sociodemographic
features
As of November 2016, a total of 1009 African American SSc
patients were enrolled in the GRASP cohort from the 18
participating US academic centers (Supplementary Table 1,
http://links.lww.com/MD/C23). Comprehensive clinical and
serological data were provided for most patients (Supplementary
Table 2, http://links.lww.com/MD/C23). The sociodemographic
features of the GRASP cohort are summarized in Table 1.
There was a female predominance, 843 (84%) women. The
majority of patients were insured. More than 50% completed a
college or post-graduate education. While 43% were actively
employed, 33% required disability support. At the time of study
enrollment, 35% of patients had a history of or currently smoked
cigarettes.3.2. Disease characteristics
In total 94% patients met the 2013ACR/EULAR classification
criteria for SSc, with the remaining 6%meeting the 1980 ACR or
CREST criteria (Table 2). The majority of patients (57%) were
classified as dcSSc.
The mean age at SSc diagnosis was 42.4±13.5 years, with an
average time to diagnosis of 3.4±6.0 years from the onset of the
first symptom attributed to SSc. The mean age at onset of the first
symptom attributed to SSc was 39.1±13.7 years (Table 2).
An assessment of the general health status was scored by
the Medsger general severity scale, which uses weight loss
and hematologic measures to define disease burden.[24]
10% exhibited a severe grade 4 disease burden, with weight
loss ≥44 pounds or anemia with hematocrit <25% (Fig. 1).
3.3. Organ involvement
3.3.1. Cutaneous. A high prevalence of diffuse disease (57%)
was noted, and a predilection for the diffuse subtype was
observed in both men and women (Table 2). Themean maximum
Table 1
Socio-demographic characteristics of the Genome Research in
African American Scleroderma Patients cohort.
Socio-demographic characteristics Number, %
Sex
Male 166 (16)
Female 843 (84)
Hispanic/Latino Ethnicity 13 (2)
Insurance
None 9 (2)
Medicare 67 (12)
Medical Assistance 69 (12)
Self-pay 11 (2)
Private 415 (73)
Marital status
Single 269 (33)
Divorced 124 (15)
Separated 20 (2)
Widowed 42 (5)
Domestic partnership 6 (1)
Married 355 (44)
Education
Grade school 16 (3)
Technical/trade 36 (6)
High school 197 (33)
College 266 (44)
Post-graduate 89 (15)
Employment
Unemployed 77 (11)
Employed 297 (43)
Disability 224 (33)
Retired 87 (13)
Cigarette use 331 (35)
Age at commencement, mean±SD 20.4±7.6
Age at cessation, mean±SD 37.7±13.5
Past PPD, mean±SD 0.7±0.5
Current PPD, mean±SD. 0.7±0.4.
PPD=packs per day, SD= standard deviation.
Table 2
Clinical and serological characteristics of the Genome Research in A
Total (n=1009)
ACR/EULAR 2013 criteria fulfilled
∗
945 (94)
Age at symptom onset, mean±SD 39.1±13.7
Raynaud’s Phenomenon 39.1±13.5
Non-Raynaud’s Phenomenon 40.6±13.4
Age at diagnosis, mean±SD 42.4±13.5
Age at sample collection, mean±SD 49.1±12.9
Disease duration, years, mean±SD 9.9±8.7
Scleroderma phenotype
SSc Subtype
Limited 432 (43)
Diffuse 566 (57)
SSc Type
0 34 (3)
1 304 (30)
2 94 (9)
3 566 (57)
Maximum mRSS, mean±SD 14±11
Raynaud’s Phenomenon 975 (98)
Telangiectasia 503 (50)
Calcinosis 184 (18)
Organ system involvement
Skin 884 (96)
Skeletal muscles 237 (28)
Myopathy
Elevated muscle enzymes 150 (23)
EMG evidence 42 (7)
MRI evidence 23 (4)
Biopsy proven 36 (6)
GI tract 903 (94)
Heart 220 (24)
Kidney 140 (15)
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4mRSS for patients with dcSSc was 20±10, and 5±5 in patients
with lcSSc (Table 3). Anti-topoisomerase I (adjusted odds ratio
[OR] 1.67, 95% confidence interval [95% CI] 1.08–2.58) and
anti-RNA polymerase III (adjusted OR 2.54, 95% CI 1.36–4.75)
positivity were significantly associated with the diffuse subtype,
whereas anti-centromere positivity was found to be protective
(adjusted OR 0.14, 95% CI 0.05–0.38) (Table 4).
In bivariate analyses, higher mRSS values were associated with
male sex (difference in mRSS 4, P< .001), anti-topoisomerase I
positivity (difference in mRSS 4, P< .001) and anti-RNA
polymerase III positivity (difference in mRSS 7, P< .001).
Conversely, anti-centromere antibody positivity was associated
with lower mRSS values (difference in mRSS 8, P< .001). In
multivariate analyses, severe cutaneous involvement (mRSS≥ 30)
was significantly associated with male sex, anti-topoisomerase I,
and anti-RNA polymerase III positivity (Table 5).
50% of the GRASP cohort had telangiectasia (Table 2). In the
adjusted models, the relative odds of having telangiectasia was
4% higher for each year of disease duration and anti-RNA
polymerase III positivity was associated with over 50% lower
odds of exhibiting telangiectasia (Table 4).
18% of patients had a history of calcinosis. Longer disease
duration was the only factor significantly associated with
calcinosis (Table 4).
3.3.2. Raynaud’s phenomenon. The mean age at onset of
Raynaud’s phenomenon (RP) was 39.1±13.5 years (Table 2).
98% of patients reported a history of RP. 31% of patients
experienced digital tip ulcerations and 6% reported complica-
tions of digital gangrene. Diffuse disease and cigarette smoking
were significantly associated with severe vascular complications
of digital ulcers and gangrene (Table 5). Older age at symptom
onset was associated with significantly lower odds of experienc-
ing these severe vascular complications (Table 5).frican American Scleroderma Patients cohort by sex.
African American scleroderma patients
Female (n=843) Male (n=166) P
789 (94) 156 (95) NA
38.6±13.7 41.7±13.4 .009
38.8±13.6 41.1±13.2 .052
40.3±13.4 42.3±13.1 .096
42.2±13.6 43.7±13.0 .196
49.0±13.0 49.6±12.0 .571
10.3±8.9 8.0±7.4 .002
380 (46) 52 (32) .001
454 (54) 112 (68)
.009
31 (4) 3 (2)
269 (32) 35 (21)
80 (10) 14 (9)
441 (54) 112 (68)
13±11 17±12 <.001
819 (98) 156 (96) .064
424 (51) 79 (48) .487
160 (19) 24 (15) .155
731 (95) 153 (98) .130
198 (28) 39 (27) .822
122 (23) 28 (24) .841
33 (7) 9 (8) .579
18 (4) 5 (5) .640
28 (6) 8 (7) .524
756 (94) 147 (94) .848
169 (22) 51 (34) .002
101 (13) 39 (25) <.001
(continued )
Table 2
(continued).
African American scleroderma patients
Total (n=1009) Female (n=843) Male (n=166) P
SSc Renal Crisis 56 (7) 43 (6) 13 (9) .144
Pulmonary 839 (88) 699 (88) 140 (89) .870
FVC% pred, mean±SD 62.6±21.3 63.0±21.4 60.7±20.8 .222
DLCO% pred, mean±SD 49.4±21.7 49.9±21.2 46.8±23.9 .113
Pulmonary Fibrosis 563 (68) 463 (68) 100 (70) .570
CXR evidence 88 (14) 66 (12) 22 (19) .064
CT Chest evidence 360 (43) 293 (43) 67 (47) .356
and FVC 50% pred 131 (38) 103 (37) 28 (44) .242
Pulmonary Hypertension 282 (30) 230 (29) 52 (34) .242
ECHO PH 189 (20) 157 (20) 32 (21) .790
Cath PH 167 (18) 137 (18) 30 (20) .499
Autoantibodies
Anti-centromere 72 (8) 68 (10) 4 (3) .008
Anti-topoisomerase I 270 (30) 213 (28) 57 (38) .017
Anti-RNA polymerase III 79 (13) 67 (13) 12 (12) .726
Anti-U1 RNP 142 (18) 120 (18) 22 (17) .818
Anti-U3 RNP 18 (14) 16 (16) 2 (8) .526
Anti-Th/To 5 (8) 5 (10) 0 (0) .582
Anti-PmScl 7 (6) 7 (7) 0 (0) .342
Anti-Smith 50 (6) 44 (7) 6 (5) .417
Anti-Ro 137 (17) 119 (17) 18 (14) .318
Anti-La 27 (3) 24 (4) 3 (2) .602
Anti-dsDNA 47 (9) 39 (9) 8 (9) .907
Antinuclear 898 (94) 750 (94) 148 (94) .970
ANA pattern .104
Centromere 48 (6) 46 (7) 2 (2)
Homogenous 69 (9) 58 (9) 11 (9)
Nucleolar 268 (36) 227 (36) 41 (34)
Speckled 226 (30) 186 (30) 40 (33)
Cytoplasmic 2 (0.3) 2 (0.3) 0 (0.0)
Diffuse 5 (0.7) 3 (0.5) 2 (1.7)
Mixed 127 (17) 102 (16) 25 (21)
Overlapping disease 204 (20) 177 (21) 27 (16) .165
Rheumatoid arthritis 37 (4) 36 (4) 1 (0.6) .021
Systemic lupus erythematosus 64 (6) 64 (8) 0 (0) <.001
Inflammatory myopathy 87 (9) 70 (8) 17 (10) .416
Sjögren’s syndrome 14 (1) 11 (1) 3 (2) .713
Other 16 (2) 10 (1) 6 (4) .022
Cancer 36 (5) 30 (5) 6 (5) .822
Comorbid conditions
CAD 45 (6) 32 (5) 13 (11) .018
ASCVD 27 (4) 25 (4) 2 (2) .208
Hypertension 368 (46) 302 (45) 66 (49) .408
Hyperlipidemia 122 (17) 99 (16) 23 (20) .321
Diabetes mellitus 65 (8) 52 (8) 13 (10) .363
COPD 46 (6) 33 (5) 13 (11) .026
Immunosuppressive medications
None 176 (21) 143 (21) 33 (24) .347
Prednisone 473 (53) 401 (54) 72 (48) .190
Methotrexate 186 (22) 161 (23) 25 (18) .224
Azathioprine 72 (9) 65 (9) 7 (5) .120
Cyclophosphamide 113 (13) 83 (12) 30 (21) .002
Mycophenolate mofetil 321 (37) 259 (36) 62 (43) .125
Hydroxycholoroquine 227 (27) 206 (29) 21 (15) .001
D-Penicillamine 42 (5) 37 (5) 5 (4) .437
Minocycline 14 (2) 11 (2) 3 (2) .602
Colchicine 29 (3) 23 (3) 6 (4) .524
Anti-tumor necrosis factor 24 (3) 23 (3) 1 (1) .100
Leflunomide 10 (1) 10 (1) 0 (0) .160
Intravenous immunoglobulin 27 (3) 22 (3) 5 (4) .766
Rituximab 25 (3) 22 (3) 3 (2) .547
Except where indicated otherwise, values are the number (%) of patients.
∗
The remaining met ACR 1980 or CREST criteria.
ANA= antinuclear antibody, ASCVD=atherosclerotic cardiovascular disease, CAD=coronary artery disease, COPD= chronic obstructive pulmonary disease, CT=computed tomography, CXR= chest x-ray,
DLCO% pred=diffusing capacity of the lung for carbon monoxide percent of predicted, ECHO= echocardiogram, EMG=electromyogram, FVC% pred= forced vital capacity percent of predicted, MRI=magnetic
resonance imaging, mRSS=modified Rodnan skin score, PH=pulmonary hypertension, SSc= systemic sclerosis.
Bold values means they are statistically significant (P value< .05).
Morgan et al. Medicine (2017) 96:51 www.md-journal.com3.3.3. Pulmonary. More than half of the cohort (66%) had a
restrictive ventilatory defect with FVC 70% of predicted. The
overall mean FVC percent predicted was 63%, and mean DLCO
percent predicted was 49% (Table 2). By report 68% of patients
had pulmonary fibrosis. 43% of patients had evidence of
pulmonary fibrosis on CT chest and 38% of these patients had
a severe restrictive ventilatory defect (FVC 50% predicted)
(Table 2).
Anti-topoisomerase I positivity was associated with signifi-
cantly higher odds of pulmonary fibrosis on CT chest, and 2-fold5higher odds of a restrictive ventilatory defect with FVC70%
predicted (Table 4). The presence of a restrictive ventilatory
defect was significantly associated with cigarette smoking
(Table 4). Notably, patients with dcSSc compared to lcSSc had
approximately equal odds of demonstrating a restrictive
ventilatory defect (Table 4).
30% of patients had evidence of pulmonary hypertension on
echocardiogram or right heart cardiac catheterization.Moreover,
these patients had severe disease with a mean DLCO 42% of
predicted. In multivariate analyses, older age at symptom onset
Figure 1. Distribution of respective severity scores for organ involvement in the GRASP cohort
∗
.
∗
Respective severity scores assigned in accordance with the
revised Medsger Severity Score for systemic sclerosis.[24] GRASP = Genome Research in African American Scleroderma Patients cohort.
Morgan et al. Medicine (2017) 96:51 Medicinewas significantly associated with pulmonary hypertension
(Table 4). Furthermore, a 6% increase in odds of pulmonary
hypertension was noted with each 1 year increase in disease
duration. The diffuse subtype was protective and associated with
41% lower odds of pulmonary hypertension (Table 4).
3.3.4. Cardiac. Echocardiographic or electrocardiogram evi-
dence of cardiac disease was noted in 24% of patients. 11% of
patients had a Medsger cardiac severity score of 4, indicative of
either clinical signs of heart failure, a left ventricular ejection
fraction of <30%, an arrhythmia requiring treatment or a heart
transplant (Fig. 1).
In multivariate analyses, a significant association was noted
between cardiac involvement and older age at symptom onset
(adjusted OR 1.03 per 1 year increase in age, 95%CI 1.01–1.05),
longer disease duration (adjusted OR 1.05 per year, 95% CI
1.02–1.08), andmale sex (adjustedOR 2.00, 95%CI 1.14–3.48).
Moreover, the significance of the observed associations was
maintained, even after adjustment for atherosclerotic cardiovas-
cular disease and cardiovascular risk factors including diabetes
mellitus, hypertension, hyperlipidemia, and cigarette smoking.
The odds of severe cardiac involvement increased by 5% per
annum of disease duration (Table 5). The magnitude and
significance of this association was maintained in multivariate
analysis adjusting for atherosclerotic cardiovascular disease and
cardiovascular risk factors (adjusted OR 1.07 per 1 year increase6in age, 95% CI 1.03–1.12). Cigarette smoking was associated
with 88% higher odds of severe cardiac involvement (Table 5).
3.3.5. Gastrointestinal tract. 94% of patients had a history of
gastrointestinal tract involvement of varying severity. In the
adjusted model, anti-RNA polymerase III positivity was
associated with 63% lower odds of gastrointestinal involvement
including gastrointestinal reflux, abnormal small bowel series,
small intestinal bacterial overgrowth, malabsorption syndrome,
episodes of pseudo-obstruction or the requirement of total
parenteral nutrition (adjusted OR 0.37, 95% CI 0.14–0.96).
Notably, 11% of patients experienced severe gastrointestinal
complications such as malabsorption syndrome, pseudo-obstruc-
tion, or required total parenteral nutrition. The diffuse subtype
was associated with over 2-fold higher odds of severe
gastrointestinal complications (Table 5).
3.3.6. Renal. Normal renal function was noted in 85% of
patients. The prevalence of scleroderma renal crisis (SRC) in the
GRASP cohort was 7% (Table 2). In bivariate analyses, SRC was
significantly associated with the diffuse subtype (OR 3.30, 95%
CI 1.68–6.47). Additionally, anti-RNA polymerase III positivity
was associated with more than 4-fold increased odds of SRC (OR
4.03, 95% CI 1.85–8.77). The significant association with anti-
RNA polymerase III positivity, but not diffuse subtype, was
maintained in the adjusted model (Table 4).
Table 3
Clinical and serological characteristics of the GenomeResearch in
African American Scleroderma Patients cohort by Scleroderma
subtype.
Limited SSc
(n=432)
Diffuse SSc
(n=566) P
Sex .001
Male 52 (12) 112 (20)
Female 380 (88) 454 (80)
Age at symptom onset, mean±SD 38.5±13.7 39.5±13.6 .215
Raynaud’s Phenomenon 38.4±13.6 39.6±13.5 .199
Non-Raynaud’s Phenomenon 41.1±13.4 40.3±13.4 .327
Disease duration (years), mean±SD 12.8±9.9 7.6±7.0 <.001
Maximum mRSS, mean±SD 5±5 20±10 <.001
Raynaud’s Phenomenon 420 (98) 547 (98) .958
Telangiectasia 222 (52) 279 (50) .506
Calcinosis 78 (18) 104 (19) .892
Organ system involvement
Skeletal muscles 75 (20) 160 (35) <.001
GI tract 383 (93) 512 (95) .113
Heart 95 (24) 125 (25) .890
Kidney 64 (16) 76 (15) .578
SSc Renal Crisis 11 (3) 45 (9) <.001
Pulmonary 357 (87) 473 (89) .444
FVC% pred, mean±SD 62.2±21.9 62.9±21.0 .661
DLCO% pred, mean±SD 48.0±21.6 50.4±21.8 .124
Pulmonary fibrosis 243 (69) 313 (68) .579
CXR evidence 38 (14) 48 (13) .974
CT chest evidence 160 (47) 194 (41) .101
and FVC 50% pred 65 (42) 64 (35) .206
Pulmonary Hypertension 142 (35) 140 (27) .016
ECHO PH 92 (22) 97 (19) .187
Cath PH 92 (22) 75 (15) .002
Autoantibodies
Anti-centromere 65 (18) 6 (1) <.001
Anti-topoisomerase I 92 (24) 172 (33) .004
Anti-RNA polymerase III 19 (8) 60 (16) .003
Anti-U1 RNP 72 (22) 70 (16) .026
Anti-U3 RNP 6 (11) 11 (16) .422
Anti-Th/To 4 (15) 1 (3) .100
Anti-PmScl 5 (10) 1 (2) .045
Anti-Smith 27 (8) 23 (5) .077
Anti-Ro 74 (22) 63 (14) .003
Anti-La 14 (4) 13 (3) .329
Anti-dsDNA 28 (11) 19 (7) .100
Antinuclear 384 (94) 505 (94) .983
Overlapping autoimmune disease 99 (23) 100 (18) .040
Rheumatoid arthritis 21 (5) 14 (2) .042
Systemic lupus erythematosus 39 (9) 25 (4) .003
Inflammatory myopathy 31 (7) 53 (9) .217
Sjögren’s 6 (1) 8 (1) .974
Other 9 (2) 7 (1) .291
Except where indicated otherwise, values are the number (%) of patients.
CT= computed tomography, DLCO% pred=diffusing capacity of the lung for carbon monoxide
percent of predicted, ECHO= echocardiogram, FVC% pred= forced vital capacity percent of
predicted, mRSS=modified Rodnan skin score, PH=pulmonary hypertension, SSc= systemic
sclerosis.
Bold values means they are statistically significant (P value < .05).
Morgan et al. Medicine (2017) 96:51 www.md-journal.com3.3.7. Muscle. 237 (28%) patients had an abnormal muscle
severity score indicating weakness. Patients with dcSSc had a
higher prevalence of skeletal muscle involvement (Table 3).
The diffuse subtype was associated with a 2-fold higher odds
of skeletal muscle involvement compared to limited disease
(adjusted OR 2.00, 95% CI 1.20–3.33).3.4. Serological profile
Clinical characteristics of the GRASP cohort by the serological
profile are summarized in Supplementary Table 3, http://links.7lww.com/MD/C23. 30% of patients were seropositive for anti-
topoisomerase I while only 8% were anticentromere positive
(Table 2). A low prevalence of anti-RNA polymerase III positivity
(13%) was observed; however, it is important to note that anti-
RNA polymerase III data were missing in 40% of patients, likely
because this assay was not commercially available until 2007.
A predilection for anti-topoisomerase I positivity was noted in
men, while a significantly higher prevalence of anti-centromere
positivity was observed in women (Table 2). A variety of
antinuclear antibody (ANA) patterns were observed, with the
nucleolar pattern being the most common, noted in 36% of
patients (Table 2).3.5. Overlapping autoimmune diseases
In total, 1 in 5 patients were diagnosed with an overlapping
autoimmune disease of which systemic lupus erythematosus
(SLE) and inflammatory myopathies were the most common
(Table 2). In the multivariate model which also included anti-
U1RNP positivity, seropositivity for anti-topoisomerase I was
associated with significantly lower odds of an overlapping
autoimmune disease (adjusted OR 0.53, 95% CI 0.29–0.96).
Anti-U1RNP positivity was associated with an approximately 4-
fold higher odds of exhibiting an overlapping autoimmune
disease (adjusted OR 3.99, 95% CI 2.33–6.84).3.6. Immunosuppressive therapy
A history of exposure to immunosuppressive therapy was
obtained. The immunosuppressive agents administered are
summarized in Table 2. The most commonly prescribed
immunosuppressive agents were prednisone (53%) and myco-
phenolate mofetil (37%), while cyclophosphamide was used in
13% of patients (Table 2).4. Discussion
Our study highlights sociodemographic, clinical and serological
features of the largest multicenter cohort of African American
patients with SSc. It provides insight into the factors associated
with clinically significant and severe manifestations of SSc in
African Americans and emphasizes the unique clinical features of
SSc in African Americans that differ from that reported in cohorts
of European ancestry.
The European League Against Rheumatism Scleroderma Trials
and Research (EUSTAR) cohort is the largest multinational
SSc cohort, comprised of over 7000 patients of predominantly
European ancestry.[25] Genetic studies have been conducted using
this cohort to identify SSc disease susceptibility loci.[26–28]
However, patients in the EUSTAR cohort differ in fundamental
clinical characteristics from those enrolled in GRASP. The
inferences made from genetic studies in the EUSTAR and other
cohorts of predominantly European ancestry[29–31] may not be
applicable to African American patients represented in the
GRASP cohort.
Themean age at onset of RP and the first non-RP symptomwas
39.1 and 40.6 years, respectively, in the GRASP cohort. In
contrast in the EUSTAR cohort, the mean age of onset of RP and
non-RP symptoms occurred 3 and 4 years later, respectively.[25]
This is consistent with prior studies, in which the average age at
onset of SSc-associated symptoms and subsequent diagnosis was
reported to be significantly younger in African Americans than
European Americans.[2,10,32–35]
Table 4
Factors associated with Clinical Manifestations of Systemic Sclerosis, adjusted odds ratio (95% confidence interval)
∗
.
Diffuse
Scleroderma Telangiectasia Calcinosis
Pulmonaryjj †
Fibrosis
FVC%
pred† 70
Pulmonary¶†
Hypertension
Scleroderma
Renal Crisis
Age at onset 0.99 (0.97–1.00) 0.99 (0.98–1.01) 1.00 (0.98–1.01) 1.00 (0.99–1.02) 1.00 (0.98–1.02) 1.02‡ (1.00–1.04) 1.01 (0.98–1.05)
Disease duration 0.93 (0.90–0.95) 1.04 (1.02–1.07) 1.05 (1.02–1.08) 1.02 (0.99–1.05) 1.01 (0.98–1.04) 1.06 (1.03–1.09) 1.01 (0.96–1.07)
Male sex 1.53 (0.91–2.57) 0.89 (0.56–1.42) 0.74 (0.39–1.39) 0.80 (0.47–1.36) 1.37 (0.77–2.42) 1.53 (0.87–2.69) 1.81 (0.75–4.37)
Diffuse SSc _ 1.14 (0.78–1.67) 1.36 (0.82–2.24) 0.63 (0.41–0.98) 0.91 (0.58–1.41) 0.59 (0.37–0.93) 2.45 (0.92–6.47)
subtype
ACA 0.14 (0.05–0.38) 1.47 (0.69–3.12) 0.68 (0.25–1.86) 0.45 (0.20–1.05) 0.88 (0.38–2.02) 1.52 (0.71–3.26) x
Topo I 1.67 (1.08–2.58) 0.77 (0.52–1.15) 1.57 (0.96–2.57) 2.14 (1.38–3.31) 2.05 (1.26–3.33) 1.29 (0.79–2.10) 0.53 (0.19–1.49)
RNA Pol III 2.54 (1.36–4.75) 0.43 (0.24–0.75) 1.29 (0.65–2.56) 1.00 (0.54–1.84) 0.94 (0.50–1.78) 1.22 (0.61–2.45) 2.88 (1.20–6.94)
Smoking status _ _ _ 1.41 (0.93–2.14) 1.58 (1.01–2.46) 1.19 (0.75–1.86) _
ACA= anti-centromere, FVC% pred= forced vital capacity percent of predicted, RNA Pol III= anti-RNA polymerase III, SSc subtype= scleroderma subtype, Topo I=anti-topoisomerase I.
∗
Adjusted model includes covariates: sex (male versus female), SSc subtype (diffuse versus limited), autoantibody status (positive versus negative), age at first symptom onset and disease duration in years.
† Covariate of smoking status (ever versus never smoked cigarettes) included in multivariate analysis.
‡ P= .015.
x In the adjusted model: Scleroderma renal crisis was not noted in anti-centromere antibody seropositive patients.
jj Pulmonary fibrosis evident on CT chest.
¶ Pulmonary hypertension evident on echocardiogram or right heart cardiac catheterization.
Bold values means they are statistically significant (P value < .05).
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cohort, in contrast to 37% in the EUSTAR cohort.[25] This is
of particular importance, as patients with dcSSc have more
extensive cutaneous fibrosis affecting the trunk and proximal
limbs, and are noted to exhibit a higher frequency of cardiac,
pulmonary, and renal involvement especially within the first
3 years of disease onset.[36]
Pulmonary complications are a prominent source of morbidity
andmortality in SSc[5,37–39] and African ancestry is reported to be
an independent predictor of early pulmonary involvement[6] and
severe pulmonary fibrosis.[35] Compared to the EUSTAR cohort,
participants in the GRASP cohort had a lower mean FVC %
predicted[25] (63% vs 92%). Additionally, 16% of patients in the
GRASP cohort required supplemental oxygen therapy compared
to 3% in the EUSTAR cohort.
Prior to the advent of initiation of angiotensin converting
enzyme (ACE) inhibitors for management of SRC, the 5-year
cumulative survival of patients with this potentially fatal
complication was <10%.[40] The prevalence of SRC in the
GRASP cohort was 3.5 times that observed in the EUSTAR
cohort (7% vs 2%).[25] This difference may potentially be
attributed to the higher frequency of dcSSc in the GRASP cohortTable 5
Factors associated with Severe Organ Involvement, adjusted odds r
Cutaneous Vascular† Pulmonary†
Age at onset 0.99 (0.96–1.01) 0.97 (0.95–0.98) 1.00 (0.98–1.01)
Disease duration 0.95 (0.91–1.00) 1.00 (0.98–1.03) 1.01 (0.98–1.03)
Male sex 1.97 (1.02–3.80) 0.98 (0.58–1.65) 1.11 (0.67–1.82)
Diffuse SSc _ 2.28 (1.47–3.52) 0.78 (0.52–1.17)
subtype
ACA 0.42 (0.05–3.24) 1.47 (0.67–3.23) 0.68 (0.32–1.42)
Topo I 2.09 (1.14–3.86) 1.40 (0.91–2.16) 1.25 (0.82–1.90)
RNA Pol III 3.00 (1.41–6.38) 0.54 (0.28–1.04) 0.74 (0.41–1.35)
Smoking status _ 2.01 (1.33–3.06) 1.41 (0.95–2.09)
ACA= anti-centromere, RNA Pol III= anti-RNA polymerase III, SSc subtype= scleroderma subtype, Topo
∗
Adjusted model includes covariates: sex (male versus female), SSc subtype (diffuse versus limited), auto
† Covariate of smoking status (ever versus never smoked cigarettes) included in multivariate analysis.
‡ In the adjusted model, severe muscle involvement was not noted in anti-centromere antibody seropos
x Severe renal disease was not noted in anti-centromere antibody seropositive patients.
Bold values means they are statistically significant (P value < .05).
8or the higher seroprevalence of anti-RNA polymerase III in the
GRASP (13% vs 2%) compared to the EUSTAR cohort.[25]
The frequency of anti-topoisomerase I positivity in African
American SSc cohorts is estimated to range from 16% to
39%.[2,8,10,32,33,35,41,42] 30% of patients in the GRASP cohort
were anti-topoisomerase I positive. Interestingly, a slightly higher
prevalence of anti-topoisomerase I positivity (37%)was observed
in the EUSTAR cohort.[25] Additionally, while the prevalence of
anti-RNA polymerase III positivity in the GRASP cohort (13%)
was consistent with prior estimates from other African American
SSc cohorts[32,35,41] it was 6 times higher than that observed in the
EUSTAR cohort (13% vs 2%).[25] This suggests that differences
exist in the serological profiles among SSc patients of African and
European ancestry, thereby limiting the generalizability of the
EUSTAR reports.
Anti-centromere antibody positivity was lower (8% vs 32%)
and anti-U1 RNP positivity was higher (18% vs 8%) in the
GRASP compared to EUSTAR cohort.[25] Unfortunately,
serological data on anti-U3 RNP and other nucleolar autoanti-
bodies were not uniformly available for patients in the GRASP
cohort, limiting our ability to make reliable inferences about the
prevalence of these autoantibodies. Anti-U3 RNP antibodies areatio (95% confidence interval)
∗
.
Cardiac† Muscle Gastrointestinal Renal
1.01 (0.99–1.04) 0.98 (0.92–1.05) 1.01 (0.99–1.03) 0.98 (0.94–1.03)
1.05 (1.02–1.09) 1.04 (0.95–1.15) 1.00 (0.96–1.04) 1.01 (0.94–1.09)
1.83 (0.90–3.73) 3.93 (0.80–19.35) 0.93 (0.47–1.84) 2.99 (0.93–9.59)
1.14 (0.59–2.20) 2.01 (0.33–12.42) 2.11 (1.13–3.95) 1.45 (0.41–5.18)
1.67 (0.63–4.44) NA‡ 0.79 (0.22–2.86) NAx
0.93 (0.47–1.83) 0.87 (0.15–5.13) 1.21 (0.68–2.13) 0.62 (0.16–2.41)
0.29 (0.07–1.23) 3.95 (0.67–23.35) 0.74 (0.31–1.74) 2.45 (0.62–9.71)
1.88 (1.04–3.40) _ _ _
I, anti-topoisomerase I.
antibody status (positive versus negative), age at first symptom onset and disease duration in years.
itive patients.
[8] Reveille JD, Fischbach M,McNearney T, et al. Systemic sclerosis in 3 US
Morgan et al. Medicine (2017) 96:51 www.md-journal.comreported to be highly specific for SSc and more prevalent in
African Americans,[43,44] exhibiting associations with diffuse
disease, skeletal muscle involvement, and primary pulmonary
arterial hypertension[43,45] as well as aggressive gastrointestinal
disease.[35] Of note anti-U3 RNP antibodies typically demon-
strate a nucleolar pattern on indirect immunofluorescence. This
pattern was observed in 36% of the GRASP cohort.
African American patients with SSc are reported to have
overall lower sociodemographic status and significantly fewer
years of education than European Americans.[8,10] It is noted that
97% of the GRASP cohort obtained a high school education with
59% completing college or post-graduate education. Further-
more, participants in the GRASP cohort were almost universally
insured, with 97%havingMedicare, private insurance ormedical
assistance. In light of this, the high disease burden in the GRASP
cohort is unlikely to be substantially attributed to socioeconomic
factors and impaired access to healthcare.
There are limitations to our study, primarily related to missing
data stemming from the retrospective collection of information.
In particular, while DNA samples have been uniformly provided,
for some patients the corresponding clinical and serological
information are incomplete. Nevertheless, the data gleaned from
the GRASP cohort is comprehensive, providing the most
complete phenotypic characterization of SSc in African American
patients to date.
Evidence of distinct clinical and serological differences between
SSc patients of African and European ancestry underscores the
critical importance of further research in African Americans, who
otherwise may not benefit from precision medicine through new
clinical and technological advancements in the treatment of their
disease.[46] Our study highlights sociodemographic, clinical and
serological features of this multicenter cohort of African
American patients and emphasizes the severe disease burden of
SSc in African Americans. Furthermore, GRASP provides a
unique cohort to facilitate future investigations probing the role
of genetic factors in SSc disease susceptibility and severity in
African Americans.Acknowledgments
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